Research Analysts Issue Forecasts for TNGX Q2 Earnings

Key Points

• HC Wainwright forecasts a Q2 2027 loss of $0.37 per share for Tango Therapeutics and maintains a “Buy” rating with a $68 price target. It also projects full-year 2027 losses of $1.54 per share.
• Tango Therapeutics reported a quarterly loss of $0.37 per share, missing analysts’ consensus estimate of a $0.32 loss by $0.05.
• Analyst sentiment remains broadly positive, with 13 Buy ratings, two Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $43.46.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2027 earnings estimates for shares of Tango Therapeutics in a research note issued on Tuesday, August 18th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.37) per share for the quarter. HC Wainwright has a "Buy" rating and a $68.00 price objective on the stock. The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.36) per share. HC Wainwright also issued estimates for Tango Therapeutics' Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.41) EPS and FY2027 earnings at ($1.54) EPS.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05).

Several other equities research analysts have also commented on TNGX. Stifel Nicolaus upped their price target on shares of Tango Therapeutics from $24.00 to $40.00 and gave the company a "buy" rating in a report on Monday, April 27th. JPMorgan Chase & Co. began coverage on Tango Therapeutics in a report on Wednesday, July 15th. They issued an "overweight" rating and a $46.00 price target for the company. Raymond James Financial lowered Tango Therapeutics to a "hold" rating in a research report on Thursday, June 25th. Jefferies Financial Group raised shares of Tango Therapeutics from a "hold" rating to a "buy" rating and raised their price objective for the stock from $27.00 to $60.00 in a research note on Thursday, June 25th. Finally, Canaccord Genuity Group lifted their target price on shares of Tango Therapeutics from $42.00 to $46.00 and gave the company a "buy" rating in a report on Monday, June 29th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tango Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.46.

Tango Therapeutics Trading Up 0.6%

Shares of NASDAQ:TNGX opened at $25.44 on Wednesday. Tango Therapeutics has a twelve month low of $6.25 and a twelve month high of $34.39. The company's 50 day moving average is $28.69 and its 200 day moving average is $22.51. The company has a market cap of $4.29 billion, a PE ratio of -29.93 and a beta of 1.16.

Insider Transactions at Tango Therapeutics

In other Tango Therapeutics news, insider Adam Crystal sold 27,000 shares of the firm's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the sale, the insider directly owned 115,743 shares of the company's stock, valued at approximately $3,424,835.37. This trade represents a 18.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.50% of the company's stock.

Institutional Investors Weigh In On Tango Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Allworth Financial LP acquired a new position in Tango Therapeutics during the second quarter worth $35,000. Global Retirement Partners LLC purchased a new position in Tango Therapeutics in the 2nd quarter valued at about $122,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Tango Therapeutics by 148,800.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company's stock worth $40,000 after buying an additional 4,464 shares during the last quarter. ANTIPODES PARTNERS Ltd purchased a new stake in Tango Therapeutics during the 4th quarter worth approximately $40,000. Finally, State of Wyoming acquired a new position in shares of Tango Therapeutics during the first quarter valued at approximately $128,000. Institutional investors and hedge funds own 78.99% of the company's stock.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source